WO2007019620A8 - Engineered antibodies with new world primate framework regions - Google Patents

Engineered antibodies with new world primate framework regions

Info

Publication number
WO2007019620A8
WO2007019620A8 PCT/AU2006/001165 AU2006001165W WO2007019620A8 WO 2007019620 A8 WO2007019620 A8 WO 2007019620A8 AU 2006001165 W AU2006001165 W AU 2006001165W WO 2007019620 A8 WO2007019620 A8 WO 2007019620A8
Authority
WO
WIPO (PCT)
Prior art keywords
framework regions
new world
world primate
engineered antibodies
primate framework
Prior art date
Application number
PCT/AU2006/001165
Other languages
French (fr)
Other versions
WO2007019620A1 (en
Inventor
Philip Anthony Jennings
Anthony Gerard Doyle
Adam William Clarke
Robert Daniel Gay
Original Assignee
Peptech Ltd
Philip Anthony Jennings
Anthony Gerard Doyle
Adam William Clarke
Robert Daniel Gay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2005904406A external-priority patent/AU2005904406A0/en
Application filed by Peptech Ltd, Philip Anthony Jennings, Anthony Gerard Doyle, Adam William Clarke, Robert Daniel Gay filed Critical Peptech Ltd
Priority to EP06774812A priority Critical patent/EP1945668A4/en
Priority to AU2006281980A priority patent/AU2006281980A1/en
Priority to BRPI0614430-6A priority patent/BRPI0614430A2/en
Priority to CA002619244A priority patent/CA2619244A1/en
Priority to JP2008526322A priority patent/JP2009504685A/en
Publication of WO2007019620A1 publication Critical patent/WO2007019620A1/en
Priority to US11/832,553 priority patent/US20080095767A1/en
Publication of WO2007019620A8 publication Critical patent/WO2007019620A8/en
Priority to NO20080799A priority patent/NO20080799L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)

Abstract

The present invention provides an antibody or antigen-binding portion thereof having a variable region comprising at least two complementarity determining regions (CDRs) and at least three framework regions. The the framework regions are, or are derived from New World primate framework regions, and at least one of the CDRs is a non-New World primate CDR.
PCT/AU2006/001165 2005-08-15 2006-08-15 Engineered antibodies with new world primate framework regions WO2007019620A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP06774812A EP1945668A4 (en) 2005-08-15 2006-08-15 Engineered antibodies with new world primate framework regions
AU2006281980A AU2006281980A1 (en) 2005-08-15 2006-08-15 Engineered antibodies with new world primate framework regions
BRPI0614430-6A BRPI0614430A2 (en) 2005-08-15 2006-08-15 antibody or an antigen binding portion thereof, and kit
CA002619244A CA2619244A1 (en) 2005-08-15 2006-08-15 Engineered antibodies with new world primate framework regions
JP2008526322A JP2009504685A (en) 2005-08-15 2006-08-15 Engineered antibodies using the New World primate framework region
US11/832,553 US20080095767A1 (en) 2005-08-15 2007-08-01 Engineered antibodies with new world primate framework regions
NO20080799A NO20080799L (en) 2005-08-15 2008-02-14 Reconstructed antibodies with New World primate framework regions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2005904406 2005-08-15
AU2005904406A AU2005904406A0 (en) 2005-08-15 New World Antibodies
US70933305P 2005-08-17 2005-08-17
US60/709,333 2005-08-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/832,553 Continuation US20080095767A1 (en) 2005-08-15 2007-08-01 Engineered antibodies with new world primate framework regions

Publications (2)

Publication Number Publication Date
WO2007019620A1 WO2007019620A1 (en) 2007-02-22
WO2007019620A8 true WO2007019620A8 (en) 2007-08-02

Family

ID=37757237

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2006/001165 WO2007019620A1 (en) 2005-08-15 2006-08-15 Engineered antibodies with new world primate framework regions

Country Status (9)

Country Link
US (1) US20080095767A1 (en)
EP (1) EP1945668A4 (en)
JP (1) JP2009504685A (en)
KR (1) KR20080068004A (en)
AU (1) AU2006281980A1 (en)
CA (1) CA2619244A1 (en)
NO (1) NO20080799L (en)
RU (1) RU2008110060A (en)
WO (1) WO2007019620A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1969009A4 (en) * 2005-12-20 2009-07-22 Arana Therapeutics Ltd Chimeric antibodies with part new world primate binding regions
KR20090039666A (en) 2006-02-01 2009-04-22 아라나 테라퓨틱스 리미티드 Domain antibody construct
US20080139790A1 (en) * 2006-12-08 2008-06-12 Jennings Philip A Chimeric antibodies
KR101852915B1 (en) * 2008-04-28 2018-04-27 휴머니건, 아이엔씨. Antibodies to granulocyte-macrophage colony-stimulating factor
CN104961828B (en) * 2008-06-25 2019-03-26 艾斯巴技术-诺华有限责任公司 Inhibit the stabilization and soluble antibodies of VEGF
CA2733742A1 (en) * 2008-08-14 2010-02-18 Cephalon Australia Pty Ltd Variant domain antibodies
CA2736729A1 (en) * 2008-09-29 2010-04-01 Ben Gurion University Of The Negev Research And Development Authority Amyloid beta-peptides and methods of use thereof
JP5972871B2 (en) 2010-07-20 2016-08-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド Anti-IL-23 heterodimer specific antibody
MX358739B (en) 2010-08-14 2018-09-03 Abbvie Inc Star Amyloid-beta binding proteins.
NZ604510A (en) 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
MX359070B (en) 2010-12-01 2018-09-13 Alderbio Holdings Llc Anti-ngf compositions and use thereof.
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
WO2013044298A1 (en) 2011-09-30 2013-04-04 Cephalon Australia Pty Ltd Antibodies against tl1a and uses thereof
EP2771351B1 (en) 2011-10-28 2017-06-14 Patrys Limited Pat-lm1 epitopes and methods for using same
CN105531289B (en) 2013-02-01 2019-02-22 树突细胞生物科技有限公司 Anti- CD83 antibody and application thereof
ES2667420T3 (en) 2013-02-05 2018-05-10 Engmab Sàrl Bispecific antibodies against cd3epsilon and bcma
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
EP4219552A3 (en) 2013-02-07 2023-09-13 CSL Ltd. Il-11r binding proteins and uses thereof
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
EP3074038B1 (en) 2013-11-28 2019-01-02 CSL Limited Method of treating diabetic nephropathy
DK3082860T3 (en) 2013-12-18 2021-01-25 Csl Ltd PROCEDURE FOR WOUND TREATMENT
AU2015329965A1 (en) 2014-10-09 2017-04-27 Engmab Sàrl Bispecific antibodies against CD3epsilon and ROR1
CA2965170A1 (en) 2014-10-23 2016-04-28 Dendrocyte Biotech Pty Ltd Cd83 binding proteins and uses thereof
US10940212B2 (en) 2014-12-19 2021-03-09 Monash University IL-21 agonist antibodies and methods of treatment using same
FI3447075T3 (en) 2015-05-15 2023-11-07 Massachusetts Gen Hospital Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
PL3331910T3 (en) 2015-08-03 2020-05-18 Engmab Sàrl Monoclonal antibodies against human b cell maturation antigen (bcma)
CN110023339A (en) 2016-09-23 2019-07-16 Csl有限公司 Coagulation factor binding protein and its application
JP7267914B2 (en) 2016-11-02 2023-05-02 エンクマフ エスアーエールエル Bispecific antibodies to BCMA and CD3 and immunotherapeutic agents used in combination to treat multiple myeloma
EP3697812A4 (en) 2017-10-18 2021-09-22 CSL Limited Human serum albumin variants and uses thereof
WO2019218009A1 (en) 2018-05-16 2019-11-21 Csl Limited Soluble complement receptor type 1 variants and uses thereof
WO2020168555A1 (en) * 2019-02-22 2020-08-27 武汉友芝友生物制药有限公司 Cd3 antigen binding fragment and application thereof
US11725048B2 (en) 2019-12-20 2023-08-15 Hudson Institute of Medical Research CXCL10 binding proteins and compositions thereof
WO2022013613A2 (en) 2020-07-17 2022-01-20 Onena Medicines S.L. Antibodies against lefty proteins

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5892019A (en) * 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US20030225254A1 (en) * 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090126C (en) * 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
EP0605442B1 (en) * 1991-07-25 2003-04-16 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
PT1696031E (en) * 1991-12-02 2010-06-25 Medical Res Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
JP2002512776A (en) * 1998-04-28 2002-05-08 スミスクライン・ビーチャム・コーポレイション Monoclonal antibodies with reduced immunogenicity
US7235643B2 (en) * 2000-11-07 2007-06-26 Morphotek, Inc. Antibodies and methods for generating genetically altered antibodies with high affinity
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7070995B2 (en) * 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
EP2298809A3 (en) * 2001-07-12 2012-02-15 FOOTE, Jefferson Super humanized antibodies
US7696320B2 (en) * 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20080241166A1 (en) * 2002-06-28 2008-10-02 Domantis Limited Ligands that bind a receptor
DE602004030535D1 (en) * 2003-02-19 2011-01-27 Rinat Neuroscience Corp METHOD FOR TREATING PAIN BY ADMINISTERING A NERVE GROWTH FACTOR ANTAGONIST AND A NSAID AND COMPOSITION CONTAINING THEREOF
CA2542192C (en) * 2003-06-27 2013-05-28 Bioren, Inc. Look-through mutagenesis
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
PL1648998T3 (en) * 2003-07-18 2015-03-31 Amgen Inc Specific binding agents to hepatocyte growth factor
AU2004290016A1 (en) * 2003-11-07 2005-05-26 Amgen Inc. Monkey immunoglobulin sequences
JP5042631B2 (en) * 2003-12-04 2012-10-03 バクシネックス インコーポレーティッド Method of killing tumor cells by targeting intracellular antigens exposed on apoptotic tumor cells
EP2343320B1 (en) * 2005-03-25 2017-10-25 GITR, Inc. Anti-gitr antibodies and uses thereof
EP1969009A4 (en) * 2005-12-20 2009-07-22 Arana Therapeutics Ltd Chimeric antibodies with part new world primate binding regions
KR20090039666A (en) * 2006-02-01 2009-04-22 아라나 테라퓨틱스 리미티드 Domain antibody construct
US20080139790A1 (en) * 2006-12-08 2008-06-12 Jennings Philip A Chimeric antibodies

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US9394360B2 (en) 2006-11-30 2016-07-19 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins

Also Published As

Publication number Publication date
RU2008110060A (en) 2009-09-27
NO20080799L (en) 2008-05-13
WO2007019620A1 (en) 2007-02-22
JP2009504685A (en) 2009-02-05
CA2619244A1 (en) 2007-02-22
US20080095767A1 (en) 2008-04-24
KR20080068004A (en) 2008-07-22
EP1945668A1 (en) 2008-07-23
AU2006281980A1 (en) 2007-02-22
EP1945668A4 (en) 2009-07-22

Similar Documents

Publication Publication Date Title
WO2007019620A8 (en) Engineered antibodies with new world primate framework regions
MX2008002161A (en) Chimeric antibodies with new world primate regions.
WO2007129895A3 (en) Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody
WO2006096491A3 (en) Anti-ctla-4 antibody compositions
DK1654286T3 (en) Humanized anti-CD4 antibody with immunosuppressive properties
WO2007058823A3 (en) Anti-egfr antibodies
WO2005080432A3 (en) Cdr-repaired antibodies
NZ611269A (en) Neutralizing anti-ccl20 antibodies
WO2007133290A8 (en) Anti-ox40l antibodies and methods using same
WO2007008943A3 (en) Optimized anti-ep-cam antibodies
WO2010001251A3 (en) Camelid derived antigen binding polypeptides
WO2006071441A3 (en) Antibodies directed to gpnmb and uses thereof
WO2005092926A3 (en) Reducing the risk of human and anti-human antibodies through v gene manipulation
WO2007130697A3 (en) Anti-ephb4 antibodies and methods using same
EP2025749B8 (en) Humanized anti-human osteopontin antibody
WO2013037484A8 (en) ANTI-αβTCR ANTIBODY
WO2009112245A9 (en) Antibody against the csf-1 r
WO2008079995A3 (en) Conjugate of natriuretic peptide and antibody constant region
WO2007127506A8 (en) Anti-ephrinb2 antibodies and methods using same
WO2008009960A3 (en) Anti-testosterone antibodies
WO2008110914A3 (en) Methods for producing active scfv antibodies and libraries therefor
AU2012293646A8 (en) New antibodies against phosphorylcholine
WO2022026807A3 (en) Antibodies targeting sars-cov-2 and uses thereof
UA98100C2 (en) Humanized monoclonal antibody that binds and neutralizes human nogo
WO2007072022A3 (en) Composition comprising an antigen-recognizing molecule and a lipid-based carrier

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680038157.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11832553

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 578/KOLNP/2008

Country of ref document: IN

Ref document number: 12008500361

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2006281980

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2619244

Country of ref document: CA

Ref document number: 565905

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/002162

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2008526322

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006281980

Country of ref document: AU

Date of ref document: 20060815

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006281980

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006774812

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: KR

Ref document number: 1020087006269

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2008110060

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 11832553

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2006774812

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0614430

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080215